Rebecca has been a Clinical Senior Lecturer and Consultant Medical Oncologist at UCL/UCLH since 2009. She has a specialist interest in experimental therapeutics for the treatment of gynaecological malignancies and runs an extensive portfolio of Phase I first-in-man through to Phase III academic and industry-sponsored clinical trials with associated translational research. She is leading the clinical development of Rucaparib in combination with anti-PD1 or anti-PDL1 agents in ovarian cancer and led the Phase I/II monotherapy trial for ovarian cancer that contributed to FDA approval in December 2016. Her academic work at UCL is supported by the NIHR/UCLH Biomedical Research Centre and she has received grant funding from CRUK and ECMC.
During undergraduate training at Manchester University Rebecca was awarded an Erasmus Scholarship to study at the University of Lausanne, Switzerland. She trained in medical oncology at the Royal Marsden Hospital, was awarded a PhD supported by a CRUK-funded research fellowship at the Institute of Cancer Research and completed training as a senior research fellow on the Drug Development Unit at the Royal Marsden Hospital in 2009.
Rebecca is Chair of the 2018 BGCS Scientific Committee, member of the NCRI endometrial cancer subgroup, CRUK Combinations Alliance Committee and Target Ovarian Cancer Scientific Advisory Board. Rebecca was Chair of the ASCO Gynecology Scientific Programme Committee in 2016, served on the ASCO Scientific Programme Committee 2014-2016 and was a member of the ASCO Education Committee 2016. She has an Honorary Fellowship from the Royal Society of Biology.